Navigation Links
Max Neeman Develops Innovative Approach for Rare Disease Studies

RESEARCH TRIANGLE PARK, N.C., March 1, 2011 /PRNewswire/ -- Max Neeman International has established a team of experts specialized in carrying out rare disease trials in response to sponsor demand. The team has the required expertise to develop innovative approaches to optimize complex study design.  Often strict inclusion/exclusion criteria and data analysis for rare disease studies create the greatest challenge for Biotech and Pharma that the company's expertise can address.


Max Neeman is a leading CRO in India that has a focus on Rare Disease Studies, in addition to other indications.  Patient enrollment for rare disease, complex global and multi-centric trials is challenging because potential subjects are fewer in number and widely dispersed.  India has evolved into a preferred destination for conducting such trials because of low cost and faster patient recruitment supported by the country's diverse gene pool and vast population of 1.3B.

Rare diseases are frequently life-threatening or chronically debilitating. However, drug development for these conditions has been limited by relative unavailability of subjects for clinical trials, as well as the high cost of investing in a novel pharmaceutical agent with poor market potential.  

Max Neeman International conducts India-based clinical research services for clients across the globe delivering quality results and exceptional customer service at a lower cost resulting in high client satisfaction.

About Max Neeman International

Max Neeman International is one of the leading and largest CROs in India and the clinical research arm of healthcare conglomerate, Max India.  Our specialty is that we offer services for the successful conduct of Phase I-IV clinical and device trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP standards. Operational since 2001, Max Neeman is an ISO 9001:2008 certified CRO for Monitoring, Site Management and Data Management Services. The company has 6 regional offices and 175 sites across 31 cities. Contact Donald Swankie, Vice President USA via email to or call +1.919.424.3345.

About Max Healthcare

Also part of the Max India group, Max Healthcare is one of a leading chain of hospitals in India.  State of the art infrastructure, India/Europe/USA trained physicians, and most advanced technologies make it one of the best hospitals in the country.

SOURCE Max Neeman International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Max Neeman International Expands Specialized Surgical Team for Clinical Trials
2. Max Neeman International and AMEDON Collaborate to Increase EDC Performance
3. Max Neeman International Expands Data Management Services with Conversion Into CDISC Standard Data Model
4. Max Neeman International Expands Upon Cardiology and Device Trial Experience to Meet Increased Medical Device Development in India
5. Max Neeman International Initiates Large Phase IV Trial on Type II Diabetes with 25,000 Subjects Across 1,200 Sites
6. Max Neeman International ISO 27001:2005 Certified for Information Security Management Systems
7. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
8. Nventa Develops Proprietary Vaccine Adjuvant
9. Bad News to Bad Bugs: Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity
10. Siemens Corporate Research Develops RAPID2 System for Fast Discovery of Discriminative Pathogen Signatures
11. Binghamton Research Group Develops New Cancer Treatment
Post Your Comments:
(Date:11/30/2015)... 2015 --> --> ... Market by Product (Soft Tissue, All Tissue, Dental Welding Lasers), ... and Geography - Global Forecast to 2020", published by MarketsandMarkets, ... a CAGR of 5.2% during the forecast period from 2015 ... and 62 Figures spread through 167 P ages and ...
(Date:11/30/2015)... WOODCLIFF LAKE, N.J. and SAN ... Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) ... (FDA) has accepted for filing the New Drug Application ... approved, the extended release formulation will offer patients a ... ® ) is currently approved as ...
(Date:11/30/2015)... -- Cumberland Pharmaceuticals (CPIX), today announced that A.J. Kazimi , ... 3, 2015. TIME: 3:15p.m. ET LINK: ... --> DATE: Thursday, December 3, ... --> --> This will be ... ask the company questions in real-time - both in the ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... The American Society for Clinical ... of World AIDS Day 2015. On Nov. 30, ASCP shared its “Give a minute. ... World AIDS Day and the importance of getting tested for HIV. , ASCP has ...
(Date:11/30/2015)... ... November 30, 2015 , ... According to RF ... a senior scientist at Consumer Reports as supporting a “A Call for Clarity” ... limits. , The original Nov 2015 CR story titled, “Does Cell-Phone Radiation Cause ...
(Date:11/30/2015)... ... November 30, 2015 , ... While powdered supplements and drinks can reduce ... an inventor from Chesterfield, Va., has found an easy to keep track of the ... to measure powdered contents in a canister or other container handy and readily accessible. ...
(Date:11/30/2015)... Ill. (PRWEB) , ... November 30, 2015 , ... ... Decision Support Solutions, announced at the Radiology Society of North America (RSNA) annual ... have seen over 60% growth from 2014. Throughout 2015, the company has ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... suite of automated breast density assessment and enterprise analytics solutions, here at ... 4, 2015 (South Hall booth #2377). Volpara’s quantitative breast imaging tools enable ...
Breaking Medicine News(10 mins):